Please login to the form below
seasonal influenza
This page shows the latest seasonal influenza news and features for those working in and with pharma, biotech and healthcare.
WHO announces recommended 2023-24 flu vaccines for northern hemisphere
The objectives are to:. Analyse the antigenic and genetic characteristics of the seasonal influenza viruses that are circulating, taking into consideration the available epidemiological and clinical information from individual countries and
Latest news
-
Results for GSK’s RSV vaccine candidate published in New England Journal of Medicine
Although RSV often results in mild symptoms, it can have devastating consequences for older adults and has a global burden that can approach that of seasonal influenza,” said Professor Martinón-Torres,
-
GSK and Vir Biotech amend COVID-19 research partnership
7832, and a portfolio of other therapies for respiratory diseases such as influenza. ... This is Vir’s investigational prophylactic monoclonal antibody designed to protect against seasonal and pandemic influenza.
-
Novavax initiates phase 2 combination COVID-19/flu vaccine study
the first of its kind to evaluate a combined COVID-19 and influenza vaccine. ... We believe that, like influenza, COVID-19 will also be seasonal moving forward, and that there is room in the market for new alternatives to provide better protection
-
Pfizer and BioNTech dose first patient in COVID-19/flu combination vaccine study
This is the same case for influenza, another respiratory disease that requires continuous changes to the strains used in vaccines as circulating viruses keep evolving. ... Even with existing seasonal influenza vaccines, the burden of this virus is severe
-
WHO announces recommended 2023 flu vaccines for southern hemisphere
pharmaceutical companies to develop, produce, and licence influenza vaccines for the following season. ... Around a billion people get seasonal influenza every year and the threat of an influenza pandemic is ever-present.
More from news
Approximately 1 fully matching, plus 40 partially matching documents found.
Latest Intelligence
-
How will COVID-19 affect uptake of vaccinations against other diseases?
There is still a long way to go to improve coverage rates, particularly when it comes to seasonal influenza. ... As such, policymakers are continuing to stress the importance of planning for seasonal influenza circulation this winter.
-
Biotech profile: Tom Evans, CEO, Vaccitech.
We have two recently initiated phase 2b clinical trials that will show if this type of immunity protects against illness, either when given alone, or in conjunction with seasonal influenza vaccine. ... On this front, we have initiated a 6, 000-person
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Takeda appoints head of vaccines development
Boslego will be responsible for accelerating global vaccine development activities with a focus on lead development programmes for dengue, norovirus and seasonal influenza.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- AstraZeneca’s mild combination asthma reliever approved in UK
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Bristol Myers Squibb’s Sotyktu approved by EC for plaque psoriasis
- Positive results for Almirall’s lebrikizumab in atopic dermatitis published in NEJM and BJD
- When to call in the specialists: strategy in Medical Affairs
- Time to talk about health inequalities
- Powering Rapid Cognitive Analysis with AI
- AstraZeneca and Amgen’s Tezspire recommended by NICE for severe asthma
PMHub
Aptus Health
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...
Latest intelligence
- Time to talk about health inequalities
- Health inequalities are increasingly being recognised as a crucial healthcare challenge in the UK...
- The speed of science and the pace of comms
- Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
